Volume 5, Issue 9: Managing DAA Failures in Light of New HCV Regimen Approvals
e-Viral Hepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Hepatitis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 9)
Nurses and health care professionals involved in the care of patients with Hepatitis.
After participating in this activity, the participant will demonstrate the ability to:
- Describe the risk of resistance development following unsuccessful HCV therapy
containing direct acting antivirals (DAAs).
- Discuss the impact DAA resistance and other negative predictors (eg, cirrhosis) have
on the effectiveness of newly approved retreatment options.
- Summarize effective retreatment strategies for patients who have previously failed
HCV therapy containing a direct acting antiviral.
David L. Wyles, MD
Division of Infectious Diseases
Denver Health Medical Center at the University of Colorado
- 1.00 ANCC
- 1.00 Attendance